ArticleSisli Etfal Hastanesi tip bulteni2024
Prevalence of Pancreatic Steatosis in Inflammatory Bowel Disease Patients.
Article in Sisli Etfal Hastanesi tip bulteni, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pancreatic Steatosis: Innocent Bystander or Silent Culprit?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Fatty Liver and Pancreatic Steatosis in Patients with Chronic Hepatitis B and C and Wilson's Disease.Sisli Etfal Hastanesi tip bulteni · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Inflammatory bowel diseases (IBD) are chronic, immune-mediated disorders of the gastrointestinal system. Pancreas can be affected in IBD patients with a wide array of clinical conditions including acu-te pancreatitis, abnormalities of pancreatic duct and pancreatic insufficiency. Pancreatic steatosis (PS) is an important but often overlooked pathology of pancreas. In this study, we aimed to investigate the prevalence of PS in IBD patients to reveal the possible association in between in a patient group already prone to pancreatic disease involvement. Methods: This retrospective study included 153 IBD patients who had a computed tomography scan in the last five years to evaluate the presence of PS. PS was defined as a pancreas/spleen attenuation ratio of below 0.70 in accordance with previous studies available in the literature. Demographic data, IBD subtype and treatment modality used for IBD were recorded and analyzed. Results: 78 patients had Crohn's disease and 75 patients had ulcerative colitis. Presence of PS in IBD patients was 23.5%. Age and treatment modality were found to be related to PS presence. Logistic regression analysis revealed a statistically significant relationship between PS and advanced age (p=0.000) but not with treatment modality (p=0.290). Conclusion: PS is an important pathology of the pancreas with serious complications. In an already burdensome disease like IBD, PS can add more challenges to patient management. Although a direct correlation between PS and IBD prognosis is not established in current literature, evaluation of IBD patients for PS will help in prevention and management of PS-related conditions which will improve the overall well-being of IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.